Home › Neuroendocrine Tumors › Virginia
Neuroendocrine Tumors clinical trials in Virginia
7 studies for Neuroendocrine Tumors are looking for participants at sites in Virginia.
Cities in Virginia
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Virginia, Charlottesville
- Virginia Cancer Specialists - Fairfax Office, Fairfax
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06943755Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- University of Virginia Comprehensive Cancer Center, Charlottesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- University of Virginia Cancer Center, Charlottesville
- Inova Fairfax Hospital, Falls Church
- Children's Hospital of The King's Daughters, Norfolk
- and 3 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Charlottesville
- Crinetics Study Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07129252Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.